Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis

References

• Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013;68:S10–S19.
   PubMed Web of Science ®Google Scholar
• Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68:S20–S27.
   PubMed Web of Science ®Google Scholar
• Ulrich M, Drecoll U, Stockfleth E. Emerging drugs for actinic keratosis. Expert Opin Emerg Drugs. 2010;15:545–555.
   PubMed Web of Science ®Google Scholar
• Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:S23–S24.
   PubMed Web of Science ®Google Scholar
• Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial. Cancer. 2009;115:2523–2530.
   PubMed Web of Science ®Google Scholar
• Werner RN, Stockfleth E, Connolly SM, et al. Evidence and consensus based (S3) guidelines for the treatment of actinic keratosis. 2015 [cited 2015 Aug 28]. Available from: http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous?download=23:guideline-management-of-actinic-keratoses-update-2015
   Google Scholar
• Braakhuis BJM, Tabor MP, Kummer JA, et al. A genetic explanation of slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727–1730.
   PubMed Web of Science ®Google Scholar
• Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31(Suppl 2):8–11.
   PubMedGoogle Scholar
• Berlin JM. Current and emerging treatment strategies for the treatment of actinic keratosis. Clin Cosmet Investig Dermatol. 2010;3:119–126.
   PubMedGoogle Scholar
• Flohil SC, van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam study. J Invest Dermatol. 2013;133:1971–1978.
   PubMed Web of Science ®Google Scholar
• Naldi L, Chatenoud L, Piccitto R, et al. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: results from the prevalence of actinic keratoses Italian study, 2003–2004. Arch Dermatol. 2006;142:722–726.
   PubMedGoogle Scholar
• Memon AA, Tomenson JA, Bothwell J, et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154–1159.
   PubMed Web of Science ®Google Scholar
• Rosso JQ, Kircik L, Goldenberg G, et al. Comprehensive management of actinic keratoses. J Clin Aesthet Dermatol. 2014;7(9Suppl S2-S12): S2–S12.
   Google Scholar
• Marks R, Jolley D, Lectsas S, et al. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust. 1990;152:62–66.
   PubMed Web of Science ®Google Scholar
• Werner RN, Stockfleth E, Connolly SM, et al. International league of dermatological S, European Dermatology F. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol. 2015;29:2069–2079.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Cooper EA, Feldman SR, et al. A survey of office visits for actinic keratosis as reported by NAMCS, 1990–1999. National ambulatory medical care survey. Cutis. 2002;70:8–13.
   PubMed Web of Science ®Google Scholar
• Dreno B, Amici JM, Basset-Seguin N, et al. Management of actinic keratosis: a practical report and treatment algorithm from AKTeam expert clinicians. J Eur Acad Dermatol Venereol. 2014;28:1141–1149.
   PubMed Web of Science ®Google Scholar
• Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167(Suppl 2):36–42.
   PubMed Web of Science ®Google Scholar
• Rowert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl 3):8–12.
   PubMedGoogle Scholar
• Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb). 2015;5:19–35.
   PubMed Web of Science ®Google Scholar
• Fernandez-Figueras MT, Carrato C, Saenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29:991–997.
   PubMed Web of Science ®Google Scholar
• Berman B, Amini S, Valins W, et al. Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother. 2009;10:3015–3031.
   PubMed Web of Science ®Google Scholar
• Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64:2833–2839.
   PubMed Web of Science ®Google Scholar
• Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2012;5:111–122.
   PubMedGoogle Scholar
• Braun SA, Gerber PA. Successful treatment of perianal condylomata acuminata with ingenol mebutate gel. J Dtsch Dermatol Ges. 2016;14:616–617.
   Web of Science ®Google Scholar
• Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66:486–493.
   PubMed Web of Science ®Google Scholar
• Stahlhut M, Bertelsen M, Hoyer-Hansen M, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012;11:1181–1192.
   PubMed Web of Science ®Google Scholar
• Emmert S, Haenssle HA, Zibert JR, et al. Tumor-preferential induction of immune responses and epidermal cell death in actinic keratoses by ingenol mebutate. PLoS One. 2016;11:e0160096.
   PubMed Web of Science ®Google Scholar
• Kedei N, Lundberg DJ, Toth A, et al. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004;64:3243–3255.
   PubMed Web of Science ®Google Scholar
• Gillespie SK, Zhang XD, Hersey P. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther. 2004;3:1651–1658.
   PubMed Web of Science ®Google Scholar
• Hampson P, Chahal H, Khanim F, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood. 2005;106:1362–1368.
   PubMed Web of Science ®Google Scholar
• Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177:8123–8132.
   PubMed Web of Science ®Google Scholar
• Freiberger SN, Cheng PF, Iotzova-Weiss G, et al. Ingenol mebutate signals via PKC/MEK/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2. Mol Cancer Ther. 2015;14:2132–2142.
   PubMed Web of Science ®Google Scholar
• Parker CG, Kuttruff CA, Galmozzi A, et al. Chemical proteomics identifies SLC25A20 as a functional target of the ingenol class of actinic keratosis drugs. ACS Central Science. 2017.
   PubMed Web of Science ®Google Scholar
• Hampson P, Kavanagh D, Smith E, et al., Ed. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008;57:1241–1251.
   PubMed Web of Science ®Google Scholar
• Zoschke C, Ulrich M, Sochorova M, et al. The barrier function of organotypic non-melanoma skin cancer models. J Control Release. 2016;233:10–18. Epub 2016/ 05/01.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Picato: EPAR – public assessment report 2012. [cited 2015 Jul 10]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002275/human_med_001600.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Anderson L, Jarrett M, Schmieder G, et al. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100 cm2 on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol. 2014;7:19–29.
   PubMedGoogle Scholar
• Bucko AD, Jarratt M, Stough DB, et al. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas. J Dermatolog Treat. 2018;29:74–79. Epub 2017/ 05/20.
   PubMed Web of Science ®Google Scholar
• Cozzi SJ, Ogbourne SM, James C, et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2012;132:1263–1271.
   PubMed Web of Science ®Google Scholar
• Ulrich M, Lange-Asschenfeldt S, Skak K, et al. Biological effects of ingenol mebutate gel in moderate to severe actinic fields assessed by reflectance confocal microscopy: a phase I study. J Drugs Dermatol. 2016;15:1181–1189.
   PubMed Web of Science ®Google Scholar
• Markowitz O, Schwartz M, Feldman E, et al. Defining field cancerization of the skin using noninvasive optical coherence tomography imaging to detect and monitor actinic keratosis in ingenol mebutate 0.015%- treated patients. J Clin Aesthet Dermatol. 2016;9:18–25.
   PubMedGoogle Scholar
• Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–1019.
   PubMed Web of Science ®Google Scholar
• Augustin M, Tu JH, Knudsen KM, et al. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol. 2015;72:816–821.
   PubMed Web of Science ®Google Scholar
• Pellacani G, Peris K, Guillen C, et al. A randomized trial comparing simultaneous vs sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. J Eur Acad Dermatol Venereol. 2015;29:2192–2198.
   PubMed Web of Science ®Google Scholar
• Garbe C, Basset-Seguin N, Poulin Y, et al. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study. Br J Dermatol. 2016;174:505–513.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Shumack S, Stein Gold L, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666–670.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Harwood CA, Serra-Guillen C, et al. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Br J Dermatol. 2018;178:433–442. Epub 2017/ 10/17.
   PubMed Web of Science ®Google Scholar
• Berman B, Goldenberg G, Hanke W, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol. 2014;13:154–160.
   PubMed Web of Science ®Google Scholar
• Berman B, Nestor MS, Newburger J, et al. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. J Drugs Dermatol. 2014;13:1353–1356.
   PubMed Web of Science ®Google Scholar
• Campione E, Di Prete M, Diluvio L, et al. Efficacy of ingenol mebutate gel for actinic keratosis in patients treated by thiazide diuretics. Clin Cosmet Investig Dermatol. 2016;9:405–409. Epub 2016/ 11/18.
   PubMed Web of Science ®Google Scholar
• Dosik JS, Damstra M, Udell C, et al. Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol. 2014;7:35–42.
   PubMedGoogle Scholar
• Rosen R, Marmur E, Anderson L, et al. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 2014;4:207–219.
   PubMedGoogle Scholar
• Samorano LP, Torezan LA, Sanches JA. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol. 2015;29:1822–1827. Epub 2015/ 03/03.
   PubMed Web of Science ®Google Scholar
• Jim On SC, Knudsen KM, Skov T, et al. Regression analysis of local skin reactions to predict clearance of actinic keratosis on the face in patients treated with ingenol mebutate gel: experience from randomized controlled trials. J Drugs Dermatol. 2017;16:112–114.
   PubMed Web of Science ®Google Scholar
• Mohanna M, Hofbauer G. Pronounced local skin reaction to ingenol mebutate against actinic keratosis in kidney transplant recipient without systemic adverse events. JAAD Case Rep. 2015;1:S19–22.
   PubMedGoogle Scholar
• SmpC Picato®. Picato 150 mcg/g gel. [updated 29 Apr 2016; cited 2016 Nov 29]. Available from: https://www.medicines.org.uk/emc/medicine/27246
   Google Scholar
• LEO Pharma. Picato® (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. 2015. [cited 2015 Aug 10]. Available from: https://www.picato.com/_pdf/PrescribingInformation.pdf
   Google Scholar
• Braun S, Hevezi PA. Needling-assisted drug delivery: enhanced response to ingenol mebutate after microneedling. Dermatol Surg. 2016;43:1–2.
   Web of Science ®Google Scholar
• Erlendsson AM, Taudorf EH, Eriksson AH, et al. Ablative fractional laser alters biodistribution of ingenol mebutate in the skin. Arch Dermatol Res. 2015;307:515–522.
   PubMed Web of Science ®Google Scholar
• Karmisholt KE, Haedersdal M. Ablative fractional laser intensifies treatment outcome of scalp actinic keratoses with ingenol mebutate: a case report. J Eur Acad Dermatol Venereol. 2016;30:854–855.
   PubMed Web of Science ®Google Scholar
• Hanke WC, Norlin JM, Mark Knudsen K, et al. Quality of life in treatment of ak: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat. 2016;27(5):450-455.
   PubMed Web of Science ®Google Scholar